User login
Article Type
Changed
Wed, 05/26/2021 - 13:58
Display Headline
Small victories add up to paradigm shifts for hard-to-treat tumors
Since the “war on cancer” was declared in the 1970s, our view of cancer has evolved to an array of different diseases requiring individual battles. Many have been hard-fought, with even minor improvements in patient survival proving extremely challenging. Here we describe how recent developments are beginning to change the narrative for some of these hard-to-treat tumor types.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 12(12)
Page Number
454-460
Legacy Keywords
ovarian cancer, melanoma, pancreatic cancer, PARP inhibitors, bevacizumab, ipilimumab, FOLFIRINOX, nab-paclitaxel
Sections
Article PDF
Article PDF
Since the “war on cancer” was declared in the 1970s, our view of cancer has evolved to an array of different diseases requiring individual battles. Many have been hard-fought, with even minor improvements in patient survival proving extremely challenging. Here we describe how recent developments are beginning to change the narrative for some of these hard-to-treat tumor types.
Click on the PDF icon at the top of this introduction to read the full article.
Since the “war on cancer” was declared in the 1970s, our view of cancer has evolved to an array of different diseases requiring individual battles. Many have been hard-fought, with even minor improvements in patient survival proving extremely challenging. Here we describe how recent developments are beginning to change the narrative for some of these hard-to-treat tumor types.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 12(12)
Issue
The Journal of Community and Supportive Oncology - 12(12)
Page Number
454-460
Page Number
454-460
Article Type
Display Headline
Small victories add up to paradigm shifts for hard-to-treat tumors
Display Headline
Small victories add up to paradigm shifts for hard-to-treat tumors
Legacy Keywords
ovarian cancer, melanoma, pancreatic cancer, PARP inhibitors, bevacizumab, ipilimumab, FOLFIRINOX, nab-paclitaxel
Legacy Keywords
ovarian cancer, melanoma, pancreatic cancer, PARP inhibitors, bevacizumab, ipilimumab, FOLFIRINOX, nab-paclitaxel
Sections
Citation Override
JCSO 2014;12:454-460
Disallow All Ads
Alternative CME
Article PDF Media
Document